Brexit and life sciences webinar: the impact on product authorisations and exclusivity rights
February 2017
In this webinar, recorded on 14 February 2017, Matthew Royle, Tim Worden and Paul England discuss the issues raised by Brexit for the authorisation of medicinal products and medical devices, and how the available exclusivity rights for these products may be affected.
If you have any questions on this article or would like to propose a subject to be addressed by Synapse please contact us.
Paul England
Paul is a senior associate and professional support lawyer in the Patents group based in our London office.
Latest topical issues
Rezeptortyrosinkinase II: Patent protection for a test method does not extend to test results
Previous articles
Attention returns to decisions on UPC opt-out
UK life sciences prospects post-Brexit
The CJEU on cross-border mail order trade of prescription-only medicinal products
The Treatment - A guide for life sciences companies coming to Europe
Medicines and medical devices regulation post-Brexit
The Medical Devices Regulation is coming!
European Council approves Trade Secrets Directive
Threats to sue for patent infringement - the risks
Attention returns to decisions on UPC opt-out